These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33032902)

  • 21. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.
    Kortekaas KE; Santegoets SJ; Abdulrahman Z; van Ham VJ; van der Tol M; Ehsan I; van Doorn HC; Bosse T; van Poelgeest MIE; van der Burg SH
    J Immunother Cancer; 2019 Sep; 7(1):236. PubMed ID: 31481117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonal Relationship Between Lichen Sclerosus, Differentiated Vulvar Intra-epithelial Neoplasia and Non HPV-related Vulvar Squamous Cell Carcinoma.
    Pouwer AW; VAN DEN Einden LCG; VAN DER Linden M; Hehir-Kwa JY; Yu J; Hendriks KM; Kamping EJ; Eijkelenboom A; Massuger LFAG; Bulten J; VAN Tilborg AAG; DE Hullu JA; Kuiper RP
    Cancer Genomics Proteomics; 2020; 17(2):151-160. PubMed ID: 32108037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Landscape of Vulvar Squamous Cell Carcinoma.
    Carreras-Dieguez N; Guerrero J; Rodrigo-Calvo MT; Ribera-Cortada I; Trias I; Jares P; López Del Campo R; Saco A; Munmany M; Marimon L; Ferrando M; Vega N; Del Pino M; Torné A; Ordi J; Rakislova N
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
    Kortekaas KE; Bastiaannet E; van Doorn HC; de Vos van Steenwijk PJ; Ewing-Graham PC; Creutzberg CL; Akdeniz K; Nooij LS; van der Burg SH; Bosse T; van Poelgeest MIE
    Gynecol Oncol; 2020 Dec; 159(3):649-656. PubMed ID: 32972785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HPV-independent, p53-wild-type vulvar intraepithelial neoplasia: a review of nomenclature and the journey to characterize verruciform and acanthotic precursor lesions of the vulva.
    Parra-Herran C; Nucci MR; Singh N; Rakislova N; Howitt BE; Hoang L; Gilks CB; Bosse T; Watkins JC
    Mod Pathol; 2022 Oct; 35(10):1317-1326. PubMed ID: 35437330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Molecular Sequencing of Recurrent and Multifocal Non-HPV-associated Squamous Cell Carcinoma of the Vulva.
    Pors J; Tessier-Cloutier B; Thompson E; Almadani N; Ho J; Gilks B; Huntsman D; Hoang L
    Int J Gynecol Pathol; 2021 Jul; 40(4):391-399. PubMed ID: 33323855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allelic loss in human papillomavirus-positive and -negative vulvar squamous cell carcinomas.
    Pinto AP; Lin MC; Mutter GL; Sun D; Villa LL; Crum CP
    Am J Pathol; 1999 Apr; 154(4):1009-15. PubMed ID: 10233839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned.
    van de Nieuwenhof HP; van Kempen LC; de Hullu JA; Bekkers RL; Bulten J; Melchers WJ; Massuger LF
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2061-7. PubMed ID: 19567503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic Alterations in Human Papillomavirus-Positive and -Negative Conjunctival Squamous Cell Carcinomas.
    Ramberg I; Vieira FG; Toft PB; von Buchwald C; Funding M; Nielsen FC; Heegaard S
    Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):11. PubMed ID: 34779821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational signatures and chromosome alteration profiles of squamous cell carcinomas of the vulva.
    Han MR; Shin S; Park HC; Kim MS; Lee SH; Jung SH; Song SY; Lee SH; Chung YJ
    Exp Mol Med; 2018 Feb; 50(2):e442. PubMed ID: 29422544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular heterogeneity in human papillomavirus-dependent and -independent vulvar carcinogenesis.
    Swarts DRA; Voorham QJM; van Splunter AP; Wilting SM; Sie D; Pronk D; van Beurden M; Heideman DAM; Snijders PJF; Meijer CJLM; Steenbergen RDM; Bleeker MCG
    Cancer Med; 2018 Sep; 7(9):4542-4553. PubMed ID: 30030907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Putative precancerous lesions of vulvar squamous cell carcinoma.
    Jenkins TM; Mills AM
    Semin Diagn Pathol; 2021 Jan; 38(1):27-36. PubMed ID: 32948383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
    Xing D; Liu Y; Park HJ; Baek I; Tran H; Cheang G; Novo J; Dillon J; Matoso A; Farmer E; Cheng MA; Tsai YC; Lombardo K; Conner MG; Vang R; Hung CF; Wu TC; Song W
    Hum Pathol; 2019 Oct; 92():67-80. PubMed ID: 31437519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors.
    Allo G; Yap ML; Cuartero J; Milosevic M; Ferguson S; Mackay H; Kamel-Reid S; Weinreb I; Ghazarian D; Pintilie M; Clarke BA
    Int J Gynecol Pathol; 2020 Jul; 39(4):391-399. PubMed ID: 31274700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic characterization of vulvar squamous cell carcinoma reveals differential gene expression based on clinical outcome.
    Gordinier ME; Schau GF; Pollock SB; Shields LBE; Talwalkar S
    Gynecol Oncol; 2024 Jan; 180():111-117. PubMed ID: 38086165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer.
    Sznurkowski JJ; Żawrocki A; Biernat W
    BMC Cancer; 2016 Jul; 16():465. PubMed ID: 27411473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic characterization of vulvar squamous cell carcinoma.
    Prieske K; Alawi M; Oliveira-Ferrer L; Jaeger A; Eylmann K; Burandt E; Schmalfeldt B; Joosse SA; Woelber L
    Gynecol Oncol; 2020 Sep; 158(3):547-554. PubMed ID: 32591094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of HPV-PCR, p16 and p53 immunohistochemical status on local recurrence rate and survival in patients with vulvar squamous cell carcinoma.
    Pouwer AW; Te Grootenhuis NC; Hinten F; de Bock GH; van der Zee AGJ; Melchers WJG; Oonk MHM; de Hullu JA; Hollema H; Bulten J
    Virchows Arch; 2024 Jun; 484(6):985-994. PubMed ID: 37938322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
    Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
    Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer.
    Lérias S; Esteves S; Silva F; Cunha M; Cochicho D; Martins L; Félix A
    Mod Pathol; 2020 May; 33(5):893-904. PubMed ID: 31844270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.